Secondary objectives included efficacy, pharmacokinetics, pharmacodynamics, and immunogenicity evaluations.<h4>Methods</h4>This open-label, prospective, phase 3, post-approval commitment study included patients in China aged ≥12 years with HAE due to C1 inhibitor deficiency (HAE-C1INH) (NCT05460325). This evidence concerns the gene SERPING1 and hereditary angioedema.